Edition:
United Kingdom

Tandem Diabetes Care Inc (TNDM.OQ)

TNDM.OQ on NASDAQ Stock Exchange Global Market

2.46USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,560
52-wk High
$30.00
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Tandem Diabetes Care Announces Retirement Of CFO And Successor Appointment
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Tandem Diabetes Care Inc ::TANDEM DIABETES CARE ANNOUNCES RETIREMENT OF CFO AND SUCCESSOR APPOINTMENT.SAYS CFO JOHN CAJIGAS TO RETIRE, EFFECTIVE DECEMBER 31, 2017.TANDEM DIABETES CARE SAYS LEIGH VOSSELLER, WILL BE PROMOTED TO CFO, EFFECTIVE JANUARY 1, 2018.  Full Article

Tandem Diabetes Care reports Q3 sales of $27 million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Tandem Diabetes Care Inc :Tandem Diabetes Care reports third quarter 2017 financial results.Q3 sales $27 million versus I/B/E/S view $25.9 million.Tandem Diabetes Care Inc - qtrly loss per share $3.09‍​.Tandem Diabetes Care Inc - sees ‍fy 2017 GAAP sales to be in range of $100 million to $105 million.Tandem Diabetes Care Inc - sees ‍fy 2017 non-GAAP sales to be in range of $95 million to $100 million​.Q3 earnings per share view $-3.74, revenue view $25.9 million -- Thomson Reuters I/B/E/S.  Full Article

‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Tandem Diabetes Care Inc ::‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​.Tandem diabetes care inc - ‍tandem and Dexcom are now extending terms of their welcome programs for animas customers through march 31, 2018​.  Full Article

Empery Asset Management reports 5.63 pct passive stake in Tandem Diabetes Care
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Empery Asset Management Lp::Empery Asset Management Lp reports 5.63 pct passive stake in Tandem Diabetes Care Inc <<>> as of Oct 13 - SEC filing‍​.  Full Article

Tandem Diabetes Care sees Q3 sales of about $26.5 mln to $27.5 mln
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Tandem Diabetes Care Inc ::Sees Q3 sales about $26.5 million to $27.5 million - sec filing.Tandem Diabetes - expect seasonality to have similar impact on sales in 2017.Tandem - ‍do not expect funding from completed or proposed financing to fully address substantial doubt about co's ability to continue as a going concern​.Tandem Diabetes-expectation of seasonality impact excludes about $3.5 million deferred sales&upgrade fees received with technology program expected in q3​.Tandem Diabetes Care Inc- ‍expect we will be required to raise additional capital in order to continue as a going concern​.  Full Article

Tandem Diabetes Care‍ shareholders approv reverse stock split
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Tandem Diabetes Care Inc :Tandem Diabetes Care Inc- ‍ shareholders subsequently approved reverse stock split at a ratio of 1-for-10​.  Full Article

Tandem Diabetes Care now taking orders for t:slim X2 Insulin Pump
Tuesday, 4 Oct 2016 

Tandem Diabetes Care Inc : Tandem Diabetes Care now taking orders for next-generation t:slim X2 Insulin Pump .Shipments of t:slim X2 Pump are expected to begin late October 2016.  Full Article

Tandem Diabetes Care Q2 sales $23 million
Thursday, 28 Jul 2016 

Tandem Diabetes Care Inc : Non-Gaap operating margin is estimated to be in range of negative 52 percent to negative 62 percent for FY . As of June 30, 2016, company had $56.3 million in cash, cash equivalents and short-term investments . Tandem diabetes care reports second quarter 2016 financial results, updates 2016 guidance and announces new T:SLIM X2(TM) insulin pump and associated technology upgrade program . Q2 sales $23 million versus I/B/E/S view $23.1 million .Non-Gaap sales are now estimated to be in range of $105 million to $110 million for FY.  Full Article

Tandem Diabetes says announces expanded pediatric indication of t:slim insulin pump
Tuesday, 26 Jul 2016 

Tandem Diabetes Care Inc : Fda clearance of an expanded pediatric indication for t:slim insulin pump .Expanded pediatric indication of t:slim insulin pump for ages 6 and older.  Full Article

Tandem Diabetes Care, TypeZero Technologies announce license agreement
Thursday, 21 Jul 2016 

Tandem Diabetes Care Inc : Says financial details of agreement have not been disclosed . Terms of license agreement include a worldwide, non-exclusive license for use of Typezero's AP technology in future tandem products . Tandem Diabetes Care and Typezero Technologies announce license agreement to accelerate development and commercialization of closed-loop artificial pancreas system . Agreement also provides tandem access to Typezero's future AP innovations over next five years .Anticipate research version of tandem's T:SLIM insulin pump will be used alongside Typezero's AP Technology in IDCL trial.  Full Article